Chemotherapy and peripheral neuropathy.
Chemotherapy-induced peripheral neuropathy
Features
Mechanisms
Prevention
Risk factors
Treatment
Journal
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
05
07
2021
accepted:
20
08
2021
pubmed:
27
8
2021
medline:
18
9
2021
entrez:
26
8
2021
Statut:
ppublish
Résumé
Chemotherapy-induced peripheral neurotoxicity (CIPN) is a major dose-limiting side effect of many anti-cancer agents, including taxanes, platinums, vinca alkaloids, proteasome inhibitors, immunomodulatory drugs, and antibody-drug conjugates. The resultant symptoms often persist post treatment completion and continue to impact on long-term function and quality of life for cancer survivors. At present, dose reduction remains the only strategy to prevent severe neuropathy, often leading clinicians to the difficult decision of balancing maximal treatment exposure and minimal long-lasting side effects. This review examines the clinical presentations of CIPN with each class of neurotoxic treatment, describing signs, symptoms, and long-term outcomes. We provide an update on the proposed mechanisms of nerve damage and review current data on clinical and genetic risk factors contributing to CIPN development. We also examine recent areas of research in the treatment and prevention of CIPN, with specific focus on current clinical trials and consensus recommendations for CIPN management.
Identifiants
pubmed: 34436727
doi: 10.1007/s10072-021-05576-6
pii: 10.1007/s10072-021-05576-6
doi:
Substances chimiques
Antineoplastic Agents
0
Vinca Alkaloids
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
4109-4121Subventions
Organisme : cancer institute nsw
ID : 14/TPG/1-05
Organisme : national health and medical research council
ID : 1080521
Organisme : national health and medical research council
ID : 1148595
Organisme : national health and medical research council
ID : 1132524
Organisme : national health and medical research council
ID : 1153439
Organisme : national health and medical research council
ID : 1156093
Informations de copyright
© 2021. Fondazione Società Italiana di Neurologia.
Références
Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer statistics, 2021. CA Cancer J Clin 71(1):7–33. https://doi.org/10.3322/caac.21654
doi: 10.3322/caac.21654
pubmed: 33433946
Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, Koltzenburg M et al (2013) Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin 63(6):419–437. https://doi.org/10.3322/caac.21204
doi: 10.3322/caac.21204
pubmed: 24590861
Cavaletti G, Marmiroli P (2018) Pharmacotherapy options for managing chemotherapy-induced peripheral neurotoxicity. Expert Opin Pharmacother 19(2):113–121. https://doi.org/10.1080/14656566.2017.1415326
doi: 10.1080/14656566.2017.1415326
pubmed: 29219629
Hennenfent KL, Govindan R (2006) Novel formulations of taxanes: a review. Old wine in a new bottle? Ann Oncol. 17(5):735–49. https://doi.org/10.1093/annonc/mdj100
doi: 10.1093/annonc/mdj100
pubmed: 16364960
Hershman DL, Weimer LH, Wang A, Kranwinkel G, Brafman L, Fuentes D, Awad D et al (2011) Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 125(3):767–774. https://doi.org/10.1007/s10549-010-1278-0
doi: 10.1007/s10549-010-1278-0
pubmed: 21128110
Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC et al (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358(16):1663–1671. https://doi.org/10.1056/NEJMoa0707056
doi: 10.1056/NEJMoa0707056
pubmed: 18420499
pmcid: 2743943
Cortot AB, Audigier-Valette C, Molinier O, Le Moulec S, Barlesi F, Zalcman G, Dumont P et al (2020) Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: results of the IFCT-1103 ULTIMATE study. Eur J Cancer 131:27–36. https://doi.org/10.1016/j.ejca.2020.02.022
doi: 10.1016/j.ejca.2020.02.022
pubmed: 32276179
Swain SM, Arezzo JC (2008) Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. Clin Adv Hematol Oncol 6(6):455–467
pubmed: 18567992
Timmins HC, Li T, Trinh T, Kiernan MC, Harrison M, Boyle F, Friedlander M et al (2021) Weekly paclitaxel-induced neurotoxicity in breast cancer: outcomes and dose response. Oncologist 26(5):366–374. https://doi.org/10.1002/onco.13697
doi: 10.1002/onco.13697
pubmed: 33523545
pmcid: 8100541
Postma TJ, Vermorken JB, Liefting AJ, Pinedo HM, Heimans JJ (1995) Paclitaxel-induced neuropathy. Ann Oncol 6(5):489–494. https://doi.org/10.1093/oxfordjournals.annonc.a059220
doi: 10.1093/oxfordjournals.annonc.a059220
pubmed: 7669713
Argyriou AA, Koltzenburg M, Polychronopoulos P, Papapetropoulos S, Kalofonos HP (2008) Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit Rev Oncol Hematol 66(3):218–228. https://doi.org/10.1016/j.critrevonc.2008.01.008
doi: 10.1016/j.critrevonc.2008.01.008
pubmed: 18329278
Loprinzi CL, Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A et al (2011) Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol 29(11):1472–1478. https://doi.org/10.1200/jco.2010.33.0308
doi: 10.1200/jco.2010.33.0308
pubmed: 21383290
pmcid: 3082985
Velasco R, Bruna J (2015) Taxane-induced peripheral neurotoxicity. Toxics 3(2):152–169. https://doi.org/10.3390/toxics3020152
doi: 10.3390/toxics3020152
pubmed: 29056655
pmcid: 5634686
Pachman DR, Qin R, Seisler D, Smith EM, Kaggal S, Novotny P, Ruddy KJ et al (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24(12):5059–5068. https://doi.org/10.1007/s00520-016-3373-1
doi: 10.1007/s00520-016-3373-1
pubmed: 27534963
pmcid: 5439148
Hilkens PH, Verweij J, Vecht CJ, Stoter G, van den Bent MJ (1997) Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere). Ann Oncol 8(2):187–190. https://doi.org/10.1023/a:1008245400251
doi: 10.1023/a:1008245400251
pubmed: 9093729
Argyriou AA, Briani C, Cavaletti G, Bruna J, Alberti P, Velasco R, Lonardi S et al (2013) Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study 20(5):788–794. https://doi.org/10.1111/ene.12061
doi: 10.1111/ene.12061
Staff NP, Cavaletti G, Islam B, Lustberg M, Psimaras D, Tamburin S (2019) Platinum-induced peripheral neurotoxicity: from pathogenesis to treatment. J Peripher Nerv Syst. 24(Suppl 2):S26-s39. https://doi.org/10.1111/jns.12335
doi: 10.1111/jns.12335
pubmed: 31647151
pmcid: 6818741
Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripheral neuropathy. J Neurol 249(1):9–17. https://doi.org/10.1007/pl00007853
doi: 10.1007/pl00007853
pubmed: 11954874
Pachman DR, Qin R, Seisler DK, Smith EM, Beutler AS, Ta LE, Lafky JM et al (2015) Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (Alliance). J Clin Oncol 33(30):3416–3422. https://doi.org/10.1200/jco.2014.58.8533
doi: 10.1200/jco.2014.58.8533
pubmed: 4606060
pmcid: 4606060
Beijers AJ, Mols F, Vreugdenhil G (2014) A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. Support Care Cancer 22(7):1999–2007. https://doi.org/10.1007/s00520-014-2242-z
doi: 10.1007/s00520-014-2242-z
pubmed: 24728618
Bennett BK, Park SB, Lin CS, Friedlander ML, Kiernan MC, Goldstein D (2012) Impact of oxaliplatin-induced neuropathy: a patient perspective. Support Care Cancer 20(11):2959–2967. https://doi.org/10.1007/s00520-012-1428-5
doi: 10.1007/s00520-012-1428-5
pubmed: 22426503
Albany C, Dockter T, Wolfe E, Le-Rademacher J, Wagner-Johnston N, Einhorn L, Lafky JM et al (2021) Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724). Support Care Cancer 29(2):833–840. https://doi.org/10.1007/s00520-020-05543-5
doi: 10.1007/s00520-020-05543-5
pubmed: 32500206
Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC (2011) Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist 16(5):708–716. https://doi.org/10.1634/theoncologist.2010-0248
doi: 10.1634/theoncologist.2010-0248
pubmed: 21478275
pmcid: 3228192
Briani C, Argyriou AA, Izquierdo C, Velasco R, Campagnolo M, Alberti P, Frigeni B et al (2014) Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study. J Peripher Nerv Syst 19(4):299–306. https://doi.org/10.1111/jns.12097
doi: 10.1111/jns.12097
pubmed: 25582667
Ness KK, Jones KE, Smith WA, Spunt SL, Wilson CL, Armstrong GT, Srivastava DK et al (2013) Chemotherapy-related neuropathic symptoms and functional impairment in adult survivors of extracranial solid tumors of childhood: results from the St. Jude Lifetime Cohort Study. Arch Phys Med Rehabil. 94(8):1451–7. https://doi.org/10.1016/j.apmr.2013.03.009
doi: 10.1016/j.apmr.2013.03.009
pubmed: 23537607
pmcid: 3929944
Selvy M, Pereira B, Kerckhove N, Gonneau C, Feydel G, Pétorin C, Vimal-Baguet A et al (2020) Long-term prevalence of sensory chemotherapy-induced peripheral neuropathy for 5 years after adjuvant FOLFOX chemotherapy to treat colorectal cancer: a multicenter cross-sectional study. J Clin Med. 9(8):2400. https://doi.org/10.3390/jcm9082400
doi: 10.3390/jcm9082400
pmcid: 7465246
Yoshino T, Yamanaka T, Oki E, Kotaka M, Manaka D, Eto T, Hasegawa J et al (2019) Efficacy and long-term peripheral sensory neuropathy of 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: the ACHIEVE phase 3 randomized clinical trial. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2019.2572
doi: 10.1001/jamaoncol.2019.2572
pubmed: 31513248
pmcid: 6743062
Noble RL (1990) The discovery of the vinca alkaloids–chemotherapeutic agents against cancer. Biochem Cell Biol 68(12):1344–1351
doi: 10.1139/o90-197
Islam B, Lustberg M, Staff NP, Kolb N, Alberti P, Argyriou AA (2019) Vinca alkaloids, thalidomide and eribulin-induced peripheral neurotoxicity: from pathogenesis to treatment. J Peripher Nerv Syst 24(Suppl 2):S63-s73. https://doi.org/10.1111/jns.12334
doi: 10.1111/jns.12334
pubmed: 31647152
Haim N, Epelbaum R, Ben-Shahar M, Yarnitsky D, Simri W, Robinson E (1994) Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas. Cancer 73(10):2515–2519. https://doi.org/10.1002/1097-0142(19940515)73:10%3c2515::aid-cncr2820731011%3e3.0.co;2-g
doi: 10.1002/1097-0142(19940515)73:10<2515::aid-cncr2820731011>3.0.co;2-g
pubmed: 8174048
Li T, Timmins HC, Lazarus HM, Park SB (2020) Peripheral neuropathy in hematologic malignancies – past, present and future. Blood Rev 43:100653. https://doi.org/10.1016/j.blre.2020.100653
Verstappen CC, Koeppen S, Heimans JJ, Huijgens PC, Scheulen ME, Strumberg D, Kiburg B et al (2005) Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology 64(6):1076–1077. https://doi.org/10.1212/01.Wnl.0000154642.45474.28
doi: 10.1212/01.Wnl.0000154642.45474.28
pubmed: 15781834
Lavoie Smith EM, Li L, Chiang C, Thomas K, Hutchinson RJ, Wells EM, Ho RH et al (2015) Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. J Peripher Nerv Syst 20(1):37–46. https://doi.org/10.1111/jns.12114
doi: 10.1111/jns.12114
pubmed: 25977177
Gilchrist LS, Tanner LR, Ness KK (2017) Short-term recovery of chemotherapy-induced peripheral neuropathy after treatment for pediatric non-CNS cancer. Pediatr Blood Cancer 64(1):180–187. https://doi.org/10.1002/pbc.26204
doi: 10.1002/pbc.26204
pubmed: 27567009
Tay CG, Lee V, Ong LC, Goh KJ, Ariffin H, Fong CY (2017) Vincristine-induced peripheral neuropathy in survivors of childhood acute lymphoblastic leukaemia. Pediatr Blood Cancer 64(8):e26471. https://doi.org/10.1002/pbc.26471
Kandula T, Farrar MA, Cohn RJ, Mizrahi D, Carey K, Johnston K, Kiernan MC et al (2018) Chemotherapy-induced peripheral neuropathy in long-term survivors of childhood cancer: clinical, neurophysiological, functional, and patient-reported outcomes. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2018.0963
doi: 10.1001/jamaneurol.2018.0963
pubmed: 29799906
pmcid: 6142928
Li T, Timmins HC, King T, Kiernan MC, Goldstein D, Park SB (2020) Characteristics and risk factors of bortezomib induced peripheral neuropathy: a systematic review of phase III trials. Hematol Oncol 38(3):229–243. https://doi.org/10.1002/hon.2706
doi: 10.1002/hon.2706
pubmed: 31873944
Hu B, Zhou Q, Wu T, Zhuang L, Yi L, Cao J, Yang X et al (2017) Efficacy and safety of subcutaneous versus intravenous bortezomib in multiple myeloma: a meta-analysis. Int J Clin Pharmacol Ther 55(4):329–338. https://doi.org/10.5414/cp202714
doi: 10.5414/cp202714
pubmed: 28079515
Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I et al (2016) Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 375(8):754–766. https://doi.org/10.1056/NEJMoa1606038
doi: 10.1056/NEJMoa1606038
pubmed: 27557302
Richardson PG, Laubach JP, Schlossman RL, Mitsiades C, Anderson K (2010) Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia. J Natl Compr Canc Netw 8(Suppl 1):S4-s12. https://doi.org/10.6004/jnccn.2010.0115
doi: 10.6004/jnccn.2010.0115
pubmed: 20141673
Stratogianni A, Tosch M, Schlemmer H, Weis J, Katona I, Isenmann S, Haensch CA (2012) Bortezomib-induced severe autonomic neuropathy. Clin Auton Res 22(4):199–202. https://doi.org/10.1007/s10286-012-0164-8
doi: 10.1007/s10286-012-0164-8
pubmed: 22532274
Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D et al (2009) Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol 144(6):895–903. https://doi.org/10.1111/j.1365-2141.2008.07573.x
doi: 10.1111/j.1365-2141.2008.07573.x
pubmed: 19170677
Tacchetti P, Terragna C, Galli M, Zamagni E, Petrucci MT, Pezzi A, Montefusco V et al (2014) Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. Am J Hematol 89(12):1085–1091. https://doi.org/10.1002/ajh.23835
doi: 10.1002/ajh.23835
pubmed: 25159313
Delforge M, Bladé J, Dimopoulos MA, Facon T, Kropff M, Ludwig H, Palumbo A et al (2010) Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 11(11):1086–1095. https://doi.org/10.1016/s1470-2045(10)70068-1
doi: 10.1016/s1470-2045(10)70068-1
pubmed: 20932799
van de Donk NW, van der Holt B, Minnema MC, Vellenga E, Croockewit S, Kersten MJ, von dem Borne PA et al (2018) Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial. Lancet Haematol 5(10):e479–e492. https://doi.org/10.1016/s2352-3026(18)30149-2
doi: 10.1016/s2352-3026(18)30149-2
pubmed: 30290905
Marriott JB, Muller G, Stirling D, Dalgleish AG (2001) Immunotherapeutic and antitumour potential of thalidomide analogues. Expert Opin Biol Ther 1(4):675–682. https://doi.org/10.1517/14712598.1.4.675
doi: 10.1517/14712598.1.4.675
pubmed: 11727503
Zweegman S, van der Holt B, Mellqvist UH, Salomo M, Bos GM, Levin MD, Visser-Wisselaar H et al (2016) Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. Blood 127(9):1109–1116. https://doi.org/10.1182/blood-2015-11-679415
doi: 10.1182/blood-2015-11-679415
pubmed: 26802176
Miguel JS, Weisel K, Moreau P, Lacy M, Song K, Delforge M, Karlin L et al (2013) Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol 14(11):1055–1066. https://doi.org/10.1016/s1470-2045(13)70380-2
doi: 10.1016/s1470-2045(13)70380-2
pubmed: 24007748
Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM (2006) Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 24(27):4507–4514. https://doi.org/10.1200/jco.2006.05.6689
doi: 10.1200/jco.2006.05.6689
pubmed: 16940275
Fahdi IE, Gaddam V, Saucedo JF, Kishan CV, Vyas K, Deneke MG, Razek H et al (2004) Bradycardia during therapy for multiple myeloma with thalidomide. Am J Cardiol 93(8):1052–1055. https://doi.org/10.1016/j.amjcard.2003.12.061
doi: 10.1016/j.amjcard.2003.12.061
pubmed: 15081457
Stork M, Sandecká V, Boichuk I, Adam Z, Krejci M, Brozova L, Sevcikova S et al (2019) Bortezomib and thalidomide treatment results in newly diagnosed transplant-ineligible multiple myeloma patients are comparable in long-term follow-up. Klin Onkol. 32(6):445–52. https://doi.org/10.14735/amko2019445 ((Výsledky léčby bortezomibem a thalidomidem u nově diagnostikovaných netransplantovaných pacientů s mnohočetným myelomem jsou srovnatelné.))
doi: 10.14735/amko2019445
pubmed: 31842563
Dalla Torre C, Zambello R, Cacciavillani M, Campagnolo M, Berno T, Salvalaggio A, De March E et al (2016) Lenalidomide long-term neurotoxicity: clinical and neurophysiologic prospective study. Neurology 87(11):1161–1166. https://doi.org/10.1212/wnl.0000000000003093
doi: 10.1212/wnl.0000000000003093
pubmed: 27534712
Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A et al (2018) Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med 378(4):331–344. https://doi.org/10.1056/NEJMoa1708984
doi: 10.1056/NEJMoa1708984
pubmed: 29224502
Horwitz S, O’Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL et al (2019) Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet 393(10168):229–240. https://doi.org/10.1016/s0140-6736(18)32984-2
doi: 10.1016/s0140-6736(18)32984-2
pubmed: 30522922
Fanale MA, Whiting NC, Neylon E (2015) Treatment strategies to optimize outcomes with brentuximab vedotin: management of common and rare toxicities. J Target Ther Cancer 4(2):36–45
Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI et al (2015) Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 385(9980):1853–1862. https://doi.org/10.1016/s0140-6736(15)60165-9
doi: 10.1016/s0140-6736(15)60165-9
pubmed: 25796459
Mariotto S, Ferrari S, Sorio M, Benedetti F, Tridente G, Cavallaro T, Gajofatto A et al (2015) Brentuximab vedotin: axonal microtubule’s Apollyon. Blood Cancer J 5(8):e343. https://doi.org/10.1038/bcj.2015.72
doi: 10.1038/bcj.2015.72
pubmed: 26314985
pmcid: 4558596
Corbin ZA, Nguyen-Lin A, Li S, Rahbar Z, Tavallaee M, Vogel H, Salva KA et al (2017) Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of mycosis Fungoides and Sézary syndrome. J Neurooncol 132(3):439–446. https://doi.org/10.1007/s11060-017-2389-9
doi: 10.1007/s11060-017-2389-9
pubmed: 28271282
pmcid: 5955867
Tolaney SM, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M et al (2021) Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial. J Clin Oncol 39(21):2375–2385. https://doi.org/10.1200/JCO.20.03398
Tamburin S, Park SB, Alberti P, Demichelis C, Schenone A, Argyriou AA (2019) Taxane and epothilone-induced peripheral neurotoxicity: from pathogenesis to treatment. J Peripher Nerv Syst 24(Suppl 2):S40-s51. https://doi.org/10.1111/jns.12336
doi: 10.1111/jns.12336
pubmed: 31647157
Vahdat LT, Thomas ES, Roché HH, Hortobagyi GN, Sparano JA, Yelle L, Fornier MN et al (2012) Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials. Support Care Cancer 20(11):2661–2668. https://doi.org/10.1007/s00520-012-1384-0
doi: 10.1007/s00520-012-1384-0
pubmed: 22382588
pmcid: 3461204
Fukuda Y, Li Y, Segal RA (2017) A mechanistic understanding of axon degeneration in chemotherapy-induced peripheral neuropathy. Front Neurosci 11:481. https://doi.org/10.3389/fnins.2017.00481
doi: 10.3389/fnins.2017.00481
pubmed: 28912674
pmcid: 5583221
Figley MD, Gu W, Nanson JD, Shi Y, Sasaki Y, Cunnea K, Malde AK et al (2021) SARM1 is a metabolic sensor activated by an increased NMN/NAD(+) ratio to trigger axon degeneration. Neuron 109(7):1118–36.e11. https://doi.org/10.1016/j.neuron.2021.02.009
doi: 10.1016/j.neuron.2021.02.009
pubmed: 33657413
Turkiew E, Falconer D, Reed N, Höke A (2017) Deletion of Sarm1 gene is neuroprotective in two models of peripheral neuropathy. J Peripher Nerv Syst 22(3):162–171. https://doi.org/10.1111/jns.12219
doi: 10.1111/jns.12219
pubmed: 28485482
pmcid: 5585053
Gould SA, White M, Wilbrey AL, Pór E, Coleman MP, Adalbert R (2021) Protection against oxaliplatin-induced mechanical and thermal hypersensitivity in Sarm1(-/-) mice. Exp Neurol 338:113607. https://doi.org/10.1016/j.expneurol.2021.113607
doi: 10.1016/j.expneurol.2021.113607
pubmed: 33460644
Geisler S (2021) Vincristine- and bortezomib-induced neuropathies - from bedside to bench and back. Exp Neurol 336:113519. https://doi.org/10.1016/j.expneurol.2020.113519
doi: 10.1016/j.expneurol.2020.113519
pubmed: 33129841
Gill JS, Windebank AJ (1998) Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J Clin Invest 101(12):2842–2850. https://doi.org/10.1172/jci1130
doi: 10.1172/jci1130
pubmed: 9637718
pmcid: 508875
Ta LE, Espeset L, Podratz J, Windebank AJ (2006) Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 27(6):992–1002. https://doi.org/10.1016/j.neuro.2006.04.010
doi: 10.1016/j.neuro.2006.04.010
pubmed: 16797073
Stage TB, Hu S, Sparreboom A, Kroetz DL (2021) Role for drug transporters in chemotherapy-induced peripheral neuropathy. Clin Transl Sci 14(2):460–467. https://doi.org/10.1111/cts.12915
doi: 10.1111/cts.12915
pubmed: 33142018
Canta A, Pozzi E, Carozzi VA (2015) Mitochondrial dysfunction in chemotherapy-induced peripheral neuropathy (CIPN). Toxics 3(2):198–223. https://doi.org/10.3390/toxics3020198
doi: 10.3390/toxics3020198
pubmed: 29056658
pmcid: 5634687
Bobylev I, Joshi AR, Barham M, Neiss WF, Lehmann HC (2018) Depletion of mitofusin-2 causes mitochondrial damage in cisplatin-induced neuropathy. Mol Neurobiol 55(2):1227–1235. https://doi.org/10.1007/s12035-016-0364-7
doi: 10.1007/s12035-016-0364-7
pubmed: 28110471
Flatters SJL, Bennett GJ (2006) Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain 122(3):245–257. https://doi.org/10.1016/j.pain.2006.01.037
doi: 10.1016/j.pain.2006.01.037
pubmed: 16530964
pmcid: 1805481
Duggett NA, Griffiths LA, McKenna OE, de Santis V, Yongsanguanchai N, Mokori EB, Flatters SJ (2016) Oxidative stress in the development, maintenance and resolution of paclitaxel-induced painful neuropathy. Neuroscience 333:13–26. https://doi.org/10.1016/j.neuroscience.2016.06.050
doi: 10.1016/j.neuroscience.2016.06.050
pubmed: 27393249
Cirrincione AM, Pellegrini AD, Dominy JR, Benjamin ME, Utkina-Sosunova I, Lotti F, Jergova S et al (2020) Paclitaxel-induced peripheral neuropathy is caused by epidermal ROS and mitochondrial damage through conserved MMP-13 activation. Sci Rep 10(1):3970. https://doi.org/10.1038/s41598-020-60990-8
doi: 10.1038/s41598-020-60990-8
pubmed: 32132628
pmcid: 7055229
Bobylev I, Joshi AR, Barham M, Ritter C, Neiss WF, Höke A, Lehmann HC (2015) Paclitaxel inhibits mRNA transport in axons. Neurobiol Dis 82:321–331. https://doi.org/10.1016/j.nbd.2015.07.006
doi: 10.1016/j.nbd.2015.07.006
pubmed: 26188177
Duggett NA, Griffiths LA, Flatters SJL (2017) Paclitaxel-induced painful neuropathy is associated with changes in mitochondrial bioenergetics, glycolysis, and an energy deficit in dorsal root ganglia neurons. Pain 158(8):1499–1508. https://doi.org/10.1097/j.pain.0000000000000939
doi: 10.1097/j.pain.0000000000000939
pubmed: 28541258
pmcid: 5515641
Argyriou AA, Bruna J, Park SB, Cavaletti G (2020) Emerging pharmacological strategies for the management of chemotherapy-induced peripheral neurotoxicity (CIPN), based on novel CIPN mechanisms. Expert Rev Neurother. 20(10):1005–16. https://doi.org/10.1080/14737175.2020.1796639
doi: 10.1080/14737175.2020.1796639
pubmed: 32667212
LaPointe NE, Morfini G, Brady ST, Feinstein SC, Wilson L, Jordan MA (2013) Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. Neurotoxicology 37:231–239. https://doi.org/10.1016/j.neuro.2013.05.008
doi: 10.1016/j.neuro.2013.05.008
pubmed: 23711742
pmcid: 4169189
Topp KS, Tanner KD, Levine JD (2000) Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat. J Comp Neurol 424(4):563–576
doi: 10.1002/1096-9861(20000904)424:4<563::AID-CNE1>3.0.CO;2-U
Alé A, Bruna J, Herrando M, Navarro X, Udina E (2015) Toxic effects of bortezomib on primary sensory neurons and Schwann cells of adult mice. Neurotox Res 27(4):430–440. https://doi.org/10.1007/s12640-014-9514-8
doi: 10.1007/s12640-014-9514-8
pubmed: 25588865
Mariotto S, Tecchio C, Sorio M, Bertolasi L, Turatti M, Tozzi MC, Benedetti F et al (2019) Clinical and neurophysiological serial assessments of brentuximab vedotin-associated peripheral neuropathy. Leuk Lymphoma 60(11):2806–2809. https://doi.org/10.1080/10428194.2019.1605068
doi: 10.1080/10428194.2019.1605068
pubmed: 31057013
Lees JG, Makker PG, Tonkin RS, Abdulla M, Park SB, Goldstein D, Moalem-Taylor G (2017) Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy. Eur J Cancer 73:22–29. https://doi.org/10.1016/j.ejca.2016.12.006
doi: 10.1016/j.ejca.2016.12.006
pubmed: 28104535
Fumagalli G, Monza L, Cavaletti G, Rigolio R, Meregalli C (2020) Neuroinflammatory process involved in different preclinical models of chemotherapy-induced peripheral neuropathy. Front Immunol 11:626687. https://doi.org/10.3389/fimmu.2020.626687
doi: 10.3389/fimmu.2020.626687
pubmed: 33613570
Zhang H, Li Y, de Carvalho-Barbosa M, Kavelaars A, Heijnen CJ, Albrecht PJ, Dougherty PM (2016) Dorsal root ganglion infiltration by macrophages contributes to paclitaxel chemotherapy-induced peripheral neuropathy. J Pain 17(7):775–786. https://doi.org/10.1016/j.jpain.2016.02.011
doi: 10.1016/j.jpain.2016.02.011
pubmed: 26979998
pmcid: 4939513
Singh SK, Spiegel S (2020) Sphingosine-1-phosphate signaling: a novel target for simultaneous adjuvant treatment of triple negative breast cancer and chemotherapy-induced neuropathic pain. Adv Biol Regul 75:100670. https://doi.org/10.1016/j.jbior.2019.100670
doi: 10.1016/j.jbior.2019.100670
pubmed: 31708456
Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr (2001) Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 276(25):22382–22387. https://doi.org/10.1074/jbc.M100938200
doi: 10.1074/jbc.M100938200
pubmed: 11297551
Robertson J, Raizer J, Hodges JS, Gradishar W, Allen JA (2018) Risk factors for the development of paclitaxel-induced neuropathy in breast cancer patients. J Peripher Nerv Syst 23(2):129–133. https://doi.org/10.1111/jns.12271
doi: 10.1111/jns.12271
pubmed: 29696771
Molassiotis A, Cheng HL, Lopez V, Au JSK, Chan A, Bandla A, Leung KT et al (2019) Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer 19(1):132. https://doi.org/10.1186/s12885-019-5302-4
doi: 10.1186/s12885-019-5302-4
pubmed: 30736741
pmcid: 6368751
Hershman DL, Till C, Wright JD, Awad D, Ramsey SD, Barlow WE, Minasian LM et al (2016) Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in southwest oncology group clinical trials. J Clin Oncol 34(25):3014–3022. https://doi.org/10.1200/jco.2015.66.2346
doi: 10.1200/jco.2015.66.2346
pubmed: 27325863
pmcid: 5012713
Mizrahi D, Park SB, Li T, Timmins HC, Trinh T, Au K, Battaglini E et al (2021) Hemoglobin, body mass index, and age as risk factors for paclitaxel- and oxaliplatin-induced peripheral neuropathy. JAMA Network Open. 4(2):e2036695-e. https://doi.org/10.1001/jamanetworkopen.2020.36695
doi: 10.1001/jamanetworkopen.2020.36695
pubmed: 33587134
pmcid: 7885037
Molassiotis A, Cheng HL, Leung KT, Li YC, Wong KH, Au JSK, Sundar R et al (2019) Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. Brain and behavior 9(6):e01312. https://doi.org/10.1002/brb3.1312
doi: 10.1002/brb3.1312
pubmed: 31063261
pmcid: 6576180
Timmins HC, Mizrahi D, Li T, Kiernan MC, Goldstein D, Park SB (2021) Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review. J Cancer Surviv. https://doi.org/10.1007/s11764-021-00988-x
doi: 10.1007/s11764-021-00988-x
pubmed: 33641031
Barginear M, Dueck AC, Allred JB, Bunnell C, Cohen HJ, Freedman RA, Hurria A et al (2019) Age and the risk of paclitaxel-induced neuropathy in women with early-stage breast cancer (alliance A151411): results from 1,881 patients from cancer and leukemia group b (CALGB) 40101. Oncologist 24(5):617–623. https://doi.org/10.1634/theoncologist.2018-0298
doi: 10.1634/theoncologist.2018-0298
pubmed: 30409792
Vincenzi B, Frezza AM, Schiavon G, Spoto C, Silvestris N, Addeo R, Catalano V et al (2013) Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. Support Care Cancer 21(5):1313–1319. https://doi.org/10.1007/s00520-012-1667-5
doi: 10.1007/s00520-012-1667-5
pubmed: 23196819
Gu J, Lu H, Chen C, Gu Z, Hu M, Liu L, Yu J et al (2021) Diabetes mellitus as a risk factor for chemotherapy-induced peripheral neuropathy: a meta-analysis. Support Care Cancer. https://doi.org/10.1007/s00520-021-06321-7
doi: 10.1007/s00520-021-06321-7
pubmed: 34458943
Battaglini E, Goldstein D, Grimison P, McCullough S, Mendoza-Jones P, Park SB (2021) Chemotherapy-induced peripheral neurotoxicity in cancer survivors: predictors of long-term patient outcomes. J Natl Compr Canc Netw 19(7):821–828. https://doi.org/10.6004/jnccn.2021.7026
Ibañez-Juliá MJ, Berzero G, Reyes-Botero G, Maisonobe T, Lenglet T, Slim M, Louis S et al (2018) Antineoplastic agents exacerbating Charcot Marie tooth disease: red flags to avoid permanent disability. Acta Oncol 57(3):403–411. https://doi.org/10.1080/0284186X.2017.1415462
doi: 10.1080/0284186X.2017.1415462
pubmed: 29243538
Sánchez-Barroso L, Apellaniz-Ruiz M, Gutiérrez-Gutiérrez G, Santos M, Roldán-Romero JM, Curras M, Remacha L et al (2019) Concomitant medications and risk of chemotherapy-induced peripheral neuropathy. Oncologist 24(8):e784–e792. https://doi.org/10.1634/theoncologist.2018-0418
doi: 10.1634/theoncologist.2018-0418
pubmed: 30470691
van Schie RM, Brüggemann RJ, Hoogerbrugge PM, te Loo DM (2011) Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia. J Antimicrob Chemother 66(8):1853–1856. https://doi.org/10.1093/jac/dkr223
doi: 10.1093/jac/dkr223
pubmed: 21652620
Zirpoli GR, McCann SE, Sucheston-Campbell LE, Hershman DL, Ciupak G, Davis W, Unger JM et al (2017) Supplement use and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221): the DELCaP study. J Natl Cancer Inst 109(12):djx098. https://doi.org/10.1093/jnci/djx098
doi: 10.1093/jnci/djx098
pmcid: 6075365
Velasco R, Santos C, Soler G, Gil-Gil M, Pernas S, Galan M, Palmero R et al (2016) Serum micronutrients and prealbumin during development and recovery of chemotherapy-induced peripheral neuropathy. J Peripher Nerv Syst 21(3):134–141. https://doi.org/10.1111/jns.12177
doi: 10.1111/jns.12177
pubmed: 27282616
Yildirim N, Cengiz M (2020) Predictive clinical factors of chronic peripheral neuropathy induced by oxaliplatin. Support Care Cancer. https://doi.org/10.1007/s00520-020-05319-x
doi: 10.1007/s00520-020-05319-x
pubmed: 31974772
Saito T, Okamura A, Inoue J, Makiura D, Doi H, Yakushijin K, Matsuoka H et al (2019) Anemia is a novel predictive factor for the onset of severe chemotherapy-induced peripheral neuropathy in lymphoma patients receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy. Oncology research. 27(4):469–74. https://doi.org/10.3727/096504018x15267574931782
doi: 10.3727/096504018x15267574931782
pubmed: 30126466
pmcid: 7848272
Argyriou AA, Bruna J, Genazzani AA, Cavaletti G (2017) Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics. Nat Rev Neurol 13(8):492–504. https://doi.org/10.1038/nrneurol.2017.88
doi: 10.1038/nrneurol.2017.88
pubmed: 28664909
Cliff J, Jorgensen AL, Lord R, Azam F, Cossar L, Carr DF, Pirmohamed M (2017) The molecular genetics of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Crit Rev Oncol Hematol 120:127–140. https://doi.org/10.1016/j.critrevonc.2017.09.009
doi: 10.1016/j.critrevonc.2017.09.009
pubmed: 29198326
Savas S, Kim DY, Ahmad MF, Shariff M, Ozcelik H (2004) Identifying functional genetic variants in DNA repair pathway using protein conservation analysis. Cancer Epidemiol Biomarkers Prev Publ Am Assoc Cancer Res Am Soc Prev Oncol 13(5):801–807
Zhang X, Jiang LP, Yin Y, Wang YD (2014) XRCC1 and XPD genetic polymorphisms and clinical outcomes of gastric cancer patients treated with oxaliplatin-based chemotherapy: a meta-analysis. Tumour Biol 35(6):5637–5645. https://doi.org/10.1007/s13277-014-1746-y
doi: 10.1007/s13277-014-1746-y
pubmed: 24590266
Whitehouse CJ, Taylor RM, Thistlethwaite A, Zhang H, Karimi-Busheri F, Lasko DD, Weinfeld M et al (2001) XRCC1 stimulates human polynucleotide kinase activity at damaged DNA termini and accelerates DNA single-strand break repair. Cell 104(1):107–117. https://doi.org/10.1016/s0092-8674(01)00195-7
doi: 10.1016/s0092-8674(01)00195-7
pubmed: 11163244
Abraham JE, Guo Q, Dorling L, Tyrer J, Ingle S, Hardy R, Vallier AL et al (2014) Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with paclitaxel. Clin Cancer Res 20(9):2466–2475. https://doi.org/10.1158/1078-0432.Ccr-13-3232
doi: 10.1158/1078-0432.Ccr-13-3232
pubmed: 24599932
Wright GEB, Amstutz U, Drögemöller BI, Shih J, Rassekh SR, Hayden MR, Carleton BC et al (2019) Pharmacogenomics of vincristine-induced peripheral neuropathy implicates pharmacokinetic and inherited neuropathy genes. Clin Pharmacol Ther 105(2):402–410. https://doi.org/10.1002/cpt.1179
doi: 10.1002/cpt.1179
pubmed: 29999516
Chua KC, Xiong C, Ho C, Mushiroda T, Jiang C, Mulkey F, Lai D et al (2020) Genomewide meta-analysis validates a role for S1PR1 in microtubule targeting agent-induced sensory peripheral neuropathy. Clin Pharmacol Ther 108(3):625–634. https://doi.org/10.1002/cpt.1958
doi: 10.1002/cpt.1958
pubmed: 32562552
Peila E, D’Agata F, Caroppo P, Orsi L, Mortara P, Cauda S, Manfredi M et al (2016) Chemotherapy-induced neurotoxicity: evidence of a protective role of CC homozygosis in the interleukin-1β gene-511 C>T polymorphism. Neurotox Res 30(3):521–529. https://doi.org/10.1007/s12640-016-9637-1
doi: 10.1007/s12640-016-9637-1
pubmed: 27270586
Leandro-García LJ, Leskelä S, Jara C, Gréen H, Avall-Lundqvist E, Wheeler HE, Dolan ME et al (2012) Regulatory polymorphisms in β-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy. Clin Cancer Res 18(16):4441–4448. https://doi.org/10.1158/1078-0432.Ccr-12-1221
doi: 10.1158/1078-0432.Ccr-12-1221
pubmed: 22718863
pmcid: 3664665
Chan A, Hertz DL, Morales M, Adams EJ, Gordon S, Tan CJ, Staff NP et al (2019) Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview. Support Care Cancer 27(10):3729–3737. https://doi.org/10.1007/s00520-019-04987-8
doi: 10.1007/s00520-019-04987-8
pubmed: 31363906
pmcid: 6728179
Diouf B, Crews KR, Lew G, Pei D, Cheng C, Bao J, Zheng JJ et al (2015) Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA 313(8):815–823. https://doi.org/10.1001/jama.2015.0894
doi: 10.1001/jama.2015.0894
pubmed: 25710658
pmcid: 4377066
Apellániz-Ruiz M, Sánchez-Barroso L, Gutiérrez-Gutiérrez G, Sereno M, García-Donás J, Åvall-Lundqvist E, Gréen H et al (2015) Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with paclitaxel–letter. Clin Cancer Res 21(13):3092–3093. https://doi.org/10.1158/1078-0432.Ccr-14-1885
doi: 10.1158/1078-0432.Ccr-14-1885
pubmed: 26133776
Leandro-García LJ, Inglada-Pérez L, Pita G, Hjerpe E, Leskelä S, Jara C, Mielgo X et al (2013) Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy. J Med Genet 50(9):599–605. https://doi.org/10.1136/jmedgenet-2012-101466
doi: 10.1136/jmedgenet-2012-101466
pubmed: 23776197
Apellániz-Ruiz M, Tejero H, Inglada-Pérez L, Sánchez-Barroso L, Gutiérrez-Gutiérrez G, Calvo I, Castelo B et al (2017) Targeted sequencing reveals low-frequency variants in epha genes as markers of paclitaxel-induced peripheral neuropathy. Clin Cancer Res 23(5):1227–1235. https://doi.org/10.1158/1078-0432.Ccr-16-0694
doi: 10.1158/1078-0432.Ccr-16-0694
pubmed: 27582484
Hertz DL, Owzar K, Lessans S, Wing C, Jiang C, Kelly WK, Patel J et al (2016) Pharmacogenetic discovery in CALGB (Alliance) 90401 and mechanistic validation of a VAC14 polymorphism that increases risk of docetaxel-induced neuropathy. Clin Cancer Res 22(19):4890–4900. https://doi.org/10.1158/1078-0432.Ccr-15-2823
doi: 10.1158/1078-0432.Ccr-15-2823
pubmed: 27143689
pmcid: 5050068
Adjei AA, Lopez CL, Schaid DJ, Sloan JA, Le-Rademacher JG, Loprinzi CL, Norman AD et al (2021) Genetic predictors of chemotherapy-induced peripheral neuropathy from paclitaxel, carboplatin and oxaliplatin: NCCTG/alliance N08C1, N08CA and N08CB study. Cancers (Basel) 13(5):1084. https://doi.org/10.3390/cancers13051084
doi: 10.3390/cancers13051084
Magrangeas F, Kuiper R, Avet-Loiseau H, Gouraud W, Guérin-Charbonnel C, Ferrer L, Aussem A et al (2016) A genome-wide association study identifies a novel locus for bortezomib-induced peripheral neuropathy in european patients with multiple myeloma. Clin Cancer Res 22(17):4350–4355. https://doi.org/10.1158/1078-0432.Ccr-15-3163
doi: 10.1158/1078-0432.Ccr-15-3163
pubmed: 27060151
pmcid: 5010494
Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, Kelley MR et al (2020) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clinical Oncology. 0(0):JCO.20.01399. https://doi.org/10.1200/jco.20.01399
doi: 10.1200/jco.20.01399
Jordan B, Margulies A, Cardoso F, Cavaletti G, Haugnes HS, Jahn P, Le Rhun E et al (2020) Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO clinical practice guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol 31(10):1306–1319. https://doi.org/10.1016/j.annonc.2020.07.003
doi: 10.1016/j.annonc.2020.07.003
pubmed: 32739407
Hershman DL, Unger JM, Crew KD, Till C, Greenlee H, Minasian LM, Moinpour CM et al (2018) Two-year trends of taxane-induced neuropathy in women enrolled in a randomized trial of acetyl-l-carnitine (SWOG S0715). J Natl Cancer Inst 110(6):669–676. https://doi.org/10.1093/jnci/djx259
doi: 10.1093/jnci/djx259
pubmed: 29361042
pmcid: 6005110
Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR et al (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309(13):1359–1367. https://doi.org/10.1001/jama.2013.2813
doi: 10.1001/jama.2013.2813
pubmed: 23549581
pmcid: 23549581
Farshchian N, Alavi A, Heydarheydari S, Moradian N (2018) Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy. Cancer Chemother Pharmacol 82(5):787–793. https://doi.org/10.1007/s00280-018-3664-y
doi: 10.1007/s00280-018-3664-y
pubmed: 30105459
Salehifar E, Janbabaei G, Hendouei N, Alipour A, Tabrizi N, Avan R (2020) Comparison of the efficacy and safety of pregabalin and duloxetine in taxane-induced sensory neuropathy: a randomized controlled trial. Clin Drug Investig 40(3):249–257. https://doi.org/10.1007/s40261-019-00882-6
doi: 10.1007/s40261-019-00882-6
pubmed: 31925721
Hirayama Y, Ishitani K, Sato Y, Iyama S, Takada K, Murase K, Kuroda H et al (2015) Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial. Int J Clin Oncol 20(5):866–871. https://doi.org/10.1007/s10147-015-0810-y
doi: 10.1007/s10147-015-0810-y
pubmed: 25762165
Trinh T, Park SB, Murray J, Pickering H, Lin CS, Martin A, Friedlander M et al (2021) Neu-horizons: neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathy-a randomised controlled trial. Support Care Cancer 29(2):1103–1110. https://doi.org/10.1007/s00520-020-05591-x
doi: 10.1007/s00520-020-05591-x
pubmed: 32607598
Timmins HC, Li T, Kiernan MC, Horvath LG, Goldstein D, Park SB (2020) Quantification of small fiber neuropathy in chemotherapy-treated patients. J Pain 21(1–2):44–58. https://doi.org/10.1016/j.jpain.2019.06.011
doi: 10.1016/j.jpain.2019.06.011
pubmed: 31325646
Guo X, Sun H, Dong J, Feng Y, Li H, Zhuang R, Wang P et al (2019) Does nab-paclitaxel have a higher incidence of peripheral neuropathy than solvent-based paclitaxel? Evidence from a systematic review and meta-analysis. Crit Rev Oncol Hematol 139:16–23. https://doi.org/10.1016/j.critrevonc.2019.04.021
doi: 10.1016/j.critrevonc.2019.04.021
pubmed: 31112878
Goldstein D, Von Hoff DD, Moore M, Greeno E, Tortora G, Ramanathan RK, Macarulla T et al (2016) Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: a subset analysis from a randomised phase III trial (MPACT). Eur J Cancer 52:85–91. https://doi.org/10.1016/j.ejca.2015.10.017
doi: 10.1016/j.ejca.2015.10.017
pubmed: 26655559